I have a much higher price target than $1.25 MB as I include value from the vaccine division, have sales figures much higher than yours ($200 million +) and also use a higher PE ratio. If the vaccines are a success and CardioCel can make solid inroads into the surgical markets for which it is applicable I have a valuation of between $3.50 and $4.
FY19 $1.25 target, page-9
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.90 |
Change
-0.100(0.56%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.00 | $17.75 | $41.64K | 2.327K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 399 | $17.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.91 | 7 | 1 |
View Market Depth
| Last trade - 12.28pm 15/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |